Literature DB >> 2978516

The colony-stimulating factor 1 (CSF-1) receptor (c-fms proto-oncogene product) and its ligand.

C W Rettenmier1, M F Roussel, C J Sherr.   

Abstract

Alterations in genes that function in normal growth and development have been linked to malignant cell transformation. The mononuclear phagocyte colony-stimulating factor (CSF-1 or M-CSF) is a polypeptide growth factor synthesized by mesenchymal cells, which stimulates the survival, proliferation, and differentiation of haematopoietic cells of the monocyte-macrophage series. Multiple forms of soluble CSF-1 are produced by proteolytic cleavage of membrane-bound precursors, some of which are stably expressed at the cell surface. The c-fms proto-oncogene encodes the CSF-1 receptor, which is composed of an extracellular ligand-binding domain linked by a single membrane-spanning segment to a cytoplasmic tyrosine-specific protein kinase domain. Whereas the tyrosine kinase activity of the normal receptor is stimulated by CSF-1, mutations in the c-fms gene can constitutively activate the kinase to provide growth-stimulatory signals in the absence of the ligand. Oncogenic activation of the c-fms gene product appears to involve removal of a negative regulatory tyrosine residue near the carboxyl terminus of the receptor and one or more additional mutations that may simulate a conformational change induced by CSF-1 binding. Expression of the human c-fms gene in mouse NIH-3T3 cells confers a CSF-1 stimulated growth phenotype, indicating that receptor transduction is sufficient for fibroblasts to respond to a haematopoietic growth factor. In contrast, the v-fms oncogene induces factor-independent growth and tumorigenicity in factor-dependent myeloid cell lines, and contributes to the development of proliferative disorders of multiple haematopoietic lineages when introduced into murine bone marrow progenitors. Aberrant expression of an endogenous c-fms gene secondary to proviral insertion and transcriptional activation has also been implicated in virus-induced myeloblastic leukaemia in mice. The c-fms and CSF-1 genes have been mapped on the long arm of human chromosome 5, a region that frequently undergoes interstitial deletions in certain haematopoietic disorders including acute myelogenous leukaemia. The study of CSF-1 and its receptor should provide information concerning the role of tyrosine kinases in regulating the normal growth and differentiation of haematopoietic cells and in contributing to their malignant transformation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2978516     DOI: 10.1242/jcs.1988.supplement_9.2

Source DB:  PubMed          Journal:  J Cell Sci Suppl        ISSN: 0269-3518


  5 in total

1.  Cyclooxygenase and lipoxygenase gene expression in the inflammogenesis of breast cancer.

Authors:  Brian M Kennedy; Randall E Harris
Journal:  Inflammopharmacology       Date:  2018-05-07       Impact factor: 4.473

2.  Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets.

Authors:  Svea Stratmann; Sara A Yones; Markus Mayrhofer; Nina Norgren; Aron Skaftason; Jitong Sun; Karolina Smolinska; Jan Komorowski; Morten Krogh Herlin; Christer Sundström; Anna Eriksson; Martin Höglund; Josefine Palle; Jonas Abrahamsson; Kirsi Jahnukainen; Monica Cheng Munthe-Kaas; Bernward Zeller; Katja Pokrovskaja Tamm; Lucia Cavelier; Linda Holmfeldt
Journal:  Blood Adv       Date:  2021-02-09

3.  The redox-sensitive transcription factor Nrf2 regulates murine hematopoietic stem cell survival independently of ROS levels.

Authors:  Akil A Merchant; Anju Singh; William Matsui; Shyam Biswal
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

4.  Phorbol 12-myristate 13-acetate-induced release of the colony-stimulating factor 1 receptor cytoplasmic domain into the cytosol involves two separate cleavage events.

Authors:  Kevin Wilhelmsen; Peter van der Geer
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

5.  Genetic variation and coronary atherosclerosis in patients with systemic lupus erythematosus.

Authors:  C P Chung; J F Solus; A Oeser; C Li; P Raggi; J R Smith; C M Stein
Journal:  Lupus       Date:  2014-04-03       Impact factor: 2.911

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.